Company Overview:

TripSitter Clinic Ltd. (CSE: KETA) through its wholly-owned subsidiary TripSitter Clinic Corp, is at the forefront of two emerging sectors: telehealth and psychedelic medicine. The Company’s consultative virtual clinic, TripSitter.Clinic, is a SaaS platform that provides care, monitoring and coaching while connecting patients with licensed physicians in the United States who can evaluate for a prescribed psychedelic treatment program of therapeutic low-dose ketamine medication. TripSitter is not a primary care physician (PCP). TripSitter.Clinic requires prospective patients to provide a diagnosis from their PCP along with other health information to their chosen TripSitter physician during the initial intake process.

This Report covers the Price Action, Technical Indicators Analysis along with the Support Levels, Resistance Levels, and Recommendations on this stock.

Fundamental Highlights:

Platform Reset to Support Future Growth: TripSitter completed a share consolidation to streamline its capital structure while maintaining its CSE listing and brand identity. With a reduced share count and the transition toward a new telehealth provider, the Company is positioning its platform for improved operational focus and a potential relaunch of patient intake to support long-term value creation.

Key Investment Risks: Execution Risk, Permitting & Regulatory Risk, Inflation, low volume, thin liquidity, etc

KETA’s Technical Observation:

The chart shows early signs of a technical base forming after a prolonged downtrend. Price is stabilizing near long-term lows, holding above key support, while RSI has rebounded above neutral levels, indicating improving momentum. A recent volume-backed uptick suggests growing buyer interest and the potential for a trend reversal if follow-through continues.

KETA’s Daily Price Chart

As per the above-mentioned price action and technical indicators analysis, a ‘Speculative Buy’ rating has been given TripSitter Clinic Ltd. (CSE: KETA) at the closing market price of CAD 0.15, as of 6^th February 2026. Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain Macro & Micro-economic data and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels as on February 6, 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Dividend Yield may vary as per the stock price movement. 

Note 5: Kalkine reports are prepared based on the stock prices captured either from REFINITIV or Trading View. Typically, REFINITIV or Trading View may reflect stock prices with a delay which could be a lag of 25-30 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and the uptrend may take a pause due to profit booking or selling interest.

Stop-loss: In general, it is a level to protect further losses in case of any unfavourable movement in the stock prices.